FANGZHOU JIANKE (06086) rose more than 5% before noon. As of the time of writing, the stock was up 5.1% to HK$2.68, with a turnover of HK$111 million. The catalyst for the movement was a recent company announcement confirming the completion of a top-up placing of 45.181 million shares, raising net proceeds of approximately HK$144.3 million. The company plans to allocate the net proceeds as follows: approximately 90% will be used to accelerate the development of its AI-driven chronic disease management platform. This includes model development and optimization, expansion of infrastructure and computing resources, recruitment of talent in AI and medical expertise, data acquisition and labeling, knowledge base development, and the launch and promotion of AI-enhanced services to reach underserved patient and doctor communities. The remaining approximately 10% is earmarked for working capital and other general corporate purposes. Notably, FANGZHOU JIANKE recently issued a positive profit alert, forecasting last year's revenue to be between RMB 3.5 billion and RMB 3.55 billion, representing a year-on-year increase of 30%. The company also expects to turn a profit, with net income projected to be in the range of RMB 7 million to RMB 10 million, compared to a loss in the previous year. Analysis from Citi suggests the company's performance is largely in line with expectations; the bank had previously forecasted 28% revenue growth for 2025 and an estimated net profit of RMB 6 million. Management attributes the rapid revenue growth to an increase in the number of patients and doctors on the platform, while the return to profitability is primarily due to revenue expansion and a decrease in share-based compensation expenses.